Neurimmune and AstraZeneca close exclusive global collaboration and license agreement to develop and commercialize NI006

Neurimmune AG has closed an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, to develop NI006, an investigational human monoclonal antibody specifically targeting misfolded transthyretin.

NI006 is designed to directly address the pathology of transthyretin amyloid cardiomyopathy (ATTR-CM) by enabling removal of amyloid fibril deposits in the heart. The antibody is currently in Phase Ib development for the treatment of ATTR-CM.

As announced previously, Alexion will be granted an exclusive, worldwide license to develop, manufacture and commercialize NI006. Neurimmune will receive an upfront payment of $30 million with the potential for additional contingent milestone payments of up to $730 million payable upon achievement of certain development, regulatory and commercial milestones, as well as low-to-mid teen royalties on net sales of any approved medicine resulting from the collaboration. Neurimmune will continue to be responsible for completion of the current Phase Ib clinical study on behalf of Alexion. Alexion will be responsible for further clinical development, manufacturing, and commercialization.